VISTAGEN THERAPEUTICS INC

Vistagen Therapeutics reports mixed results on fasedienol and a nasal spray, yet new SRX Global investment and board expansion signal steady progress in CNS drug development.

Vistagen Therapeutics shares proxy details for its Sept 10, 2026 annual meeting—board elections, exec pay vote, and audit ratification—giving shareholders clear guidance and transparency.

Vistagen Therapeutics faces a March 16 class‑action deadline and a sharp drop in short‑interest—how will legal pressure and pipeline progress shape its future?

Vistagen Therapeutics (VTGN) faces steep short‑interest decline, $23 M market cap, and a March 2026 class‑action deadline—investors must act before potential payouts vanish.

Vistagen Therapeutics faces a federal securities class action while gearing up to present its intranasal “pherines” at the TD Cowen Healthcare Conference, leaving investors to weigh legal risks against potential neuropharmacology breakthroughs and a…

Vistagen Therapeutics faces a March 1 class‑action deadline—learn why shareholders must act now, what legal claims loom, and how it could affect VTGN’s future.

Vistagen Therapeutics beats Q3 earnings and revenue expectations, expands PALISADE‑4 trial with $61.8 M, driving its intranasal CNS therapy pipeline forward.

Vistagen Therapeutics faces a financial crossroads: no pipeline progress, steep stock volatility, negative earnings, and low market value raise investor doubts about its future viability and profitability in biotech.

Vistagen Therapeutics’ stock has experienced fluctuations, reaching a 52-week high of $4.21 and a 52-week low of $1.90, amidst its focus on developing treatments for central nervous system disorders.

VistaGen Therapeutics, a clinical-stage biopharmaceutical company, is set to release its earnings report on June 17, 2025, with analysts projecting a loss of -$0.497 per share and a 215% increase in quarterly revenue.